Supplementary table 1.docx: A Phase I trial of talazoparib in patients witha dvanced hematologic malignancies
收藏数据链接：
官方服务：
资源简介：
<b>Supplementary Figure 1. </b>Dose linearity and proportionality in plasma following multiple doses of talazoparib.<b> <br> </b><b>Supplementary material. </b>Medical history of the patient in Cohort 1 who experienced possible drug-related Grade 5 neutropenic sepsis. <b>Supplementary Table 1. </b>Patient disposition by dose level and diagnosis (safety population).<sup>†</sup><b></b> <b>Supplementary Table 2. </b>Exposure to talazoparib (safety population). <b></b>
提供机构：
Taylor & Francis创建时间：
2021-10-23
